pHarmAGap.com
About pHarmAGap.com
PharmaGap Inc. has developed novel drugs targeting Protein Kinase C (PKC). The Company’s pre-clinical lead drug candidate (GAP-107B8) is being developed to treat cancer. Aberrant over-expression of PKC is associated with many types of cancer and is a validated therapeutic target. GAP-107B8 was developed employing proprietary computer models PharmaGap researchers have developed for select PKC isoforms.
